Compositions and methods for treating primary effusion lymphoma

Patent metadata

Field	Value
Publication number	US-2016136146-A1
Application number	US-201514814149-A
Country	US
Kind code	A1
Filing date	Jul 30, 2015
Priority date	Jul 30, 2014
Publication date	May 19, 2016
Grant date	—

Abstract

Methods for treating primary effusion lymphoma (PEL) are provided. The methods include administering to a patient in need thereof an effective amount of an immunomodulatory compound. Suitable immunomodulatory compounds include compounds having the formula:

wherein X in Formula IV may be independently selected from the group that includes hydrogen, a halide, an aliphatic group and an amine group.

First claim

What is claimed is:

1 . A method of treating primary effusion lymphoma (PEL) comprising administering to a patient in need thereof an effective amount of a compound selected from the group consisting of

wherein X in Formula IV and Formula V may be independently selected from the group consisting of hydrogen, a halide, an aliphatic group and an amine group.

2 . A method of inhibiting the expression of interferon regulatory factor 4 (IRF-4) in a PEL cell comprising contacting the PEL cell with an effective amount of a compound selected from the group consisting of

and, optionally, in combination with a BRD4 inhibitor,
wherein X in Formula IV and Formula V may be independently selected from the group consisting of hydrogen, a halide, an aliphatic group and an amine group.

3 . A method of treating for PEL comprising administering to a patient in need thereof an effective amount of a immunomodulatory compound and a BRD4 inhibitor.

4 . The method of claim 3 , wherein the immunomodulatory compound is a compound selected from the group consisting of Formula I, Formula II, Formula III, Formula IV, and Formula V.

5 . The method of claim 3 , wherein the BRD4 inhibitor is a compound selected from the group consisting of

6 . The method of claim 4 , wherein the BRD4 inhibitor is a compound selected from the group consisting of

7 . A pharmaceutical composition for the treatment of PEL comprising: an immunomodulatory compound and a BRD4 inhibitor.

8 . The pharmaceutical according to claim 7 , further comprising at least one excipient.

9 . The method of claim 1 , wherein the compound is administered orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes or intraperitoneally by infusion or injection.

10 . The method of claim 2 , wherein the compound is administered orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes or intraperitoneally by infusion or injection.

11 . The method of claim 3 , wherein the compound and the BRD4 inhibitor are administered orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes or intraperitoneally by infusion or injection.

12 . The method of claim 4 , wherein the compound and the BRD4 inhibitor are administered orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes or intraperitoneally by infusion or injection.

13 . The method of claim 5 , wherein the compound and the BRD4 inhibitor are administered orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes or intraperitoneally by infusion or injection.

14 . The method of claim 6 , wherein the compound and the BRD4 inhibitor are administered orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes or intraperitoneally by infusion or injection.

15 . The method of claim 1 , wherein the compound or pharmaceutically acceptable salt thereof is provided as a composition comprising the compound or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier suitable for oral, parenteral, or topical administration.

16 . The method of claim 2 , wherein the compound or pharmaceutically acceptable salt thereof is provided as a composition comprising the compound or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier suitable for oral, parenteral, or topical administration.

17 . The method of claim 3 , wherein the compound and the BRD4 inhibitor or pharmaceutically acceptable salts thereof are provided as a composition comprising the compound and the BRD4 inhibitor or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier suitable for oral, parenteral, or topical administration.

18 . The method of claim 4 , wherein the compound and the BRD4 inhibitor or pharmaceutically acceptable salts thereof are provided as a composition comprising the compound and the BRD4 inhibitor or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier suitable for oral, parenteral, or topical administration.

19 . The method of claim 5 , wherein the compound and the BRD4 inhibitor or pharmaceutically acceptable salts thereof are provided as a composition comprising the compound and the BRD4 inhibitor or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier suitable for oral, parenteral, or topical administration.

20 . The method of claim 6 , wherein the compound and the BRD4 inhibitor or pharmaceutically acceptable salts thereof are provided as a composition comprising the compound and the BRD4 inhibitor or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier suitable for oral, parenteral, or topical administration.

Assignees

• Chaudhary Preet M
• Gopalakrishnan Ramakrishnan
• Univ Southern California

Inventors

• Chaudhary Preet M
• Gopalakrishnan Ramakrishnan

Classifications

• A61K31/517

  ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title

• A61K31/454 Primary

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/551

  having two nitrogen atoms, e.g. dilazep · CPC title